The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology Drug Updates

Rheumatology Drug Updates

March 1, 2013 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Pipeline & Approvals

Anakinra (Kineret) has been approved by the Food and Drug Administration (FDA) to treat adults and children with neonatal-onset multisystem inflammatory disease (NOMID), the most severe form of cryopyrin-associated periodic syndromes (CAPS).1 Prior to this approval, anakinra was available under an Orphan Drug Designation. This is its first approval for use in children. NOMID is associated with an overproduction of interleukin-1 (IL-1) that, when left untreated, leads to hearing and visual loss, cognitive dysfunction, joint contractures, bone loss, and cartilage loss.

You Might Also Like
  • Rheumatology Drug Updates
  • Rheumatology Drug Updates
  • Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib, Bimekizumab
Explore This Issue
March 2013
Also By This Author
  • Biosimilars Update: FDA Panel Voted to Approve Biosimilars for Etanercept & Adalimumab at July Meeting

Bazedoxifene/conjugated estrogen had its New Drug Application (NDA) filed on December 13, 2012.2 The FDA Prescription Drug User Fee Act (PDUFA) date is October 3, 2013. It was submitted for the treatment of moderate to severe vasomotor symptoms, vulvar and vaginal atrophy associated with menopause, and also to prevent postmenopausal osteoporosis in nonhysterectomized women. Bazedoxifene is a selective estrogen receptor modulator that has been studied in over 7,500 postmenopausal women in the Selective estrogens, Menopause And Response to Therapy (SMART) trials. The most common adverse reactions in clinical trials were abdominal pain, muscle spasms, and vaginal yeast infection.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Canakinumab (ACZ885) is a fully human monoclonal antibody that inhibits IL-1 beta. It is currently in phase III clinical trials for treating systemic juvenile idiopathic arthritis (SJIA).3 Recent data show that it led to substantial symptom relief in young patients with SJIA (n=84). In one trial known as beta-SPECIFIC 1, 84% of canakinumab-treated SJIA patients had at least a 30% improvement in symptoms (JIA ACR30) versus 10% of placebo-treated patients. This occurred after 15 days of treatment. This benefit continued beyond 29 days (P<0.001). This was a randomized, double-blind, placebo-controlled, four-week study. In beta-SPECIFIC 2, of 177 patients who were prescribed corticosteroids, 45% of canakinumab-treated patients were able to reduce their steroid use, with 33% of patients able to completely discontinue steroids. These patients were almost three times less likely to experience a new flare. Seventy-four percent of canakinumab-treated patients remained flare-free versus 25% of placebo-treated patients (P=0.003).

Fostamitinib is an oral spleen tyrosine kinase inhibitor currently in phase III clinical trials for the treatment of rheumatoid arthritis (RA).4 Fostamatinib blocks signalling in multiple cell types involved in inflammation and tissue degradation in RA and may delay disease progression. The phase III trials, the results of which are expected by mid-2013, are known as, Oral Syk Inhibition in Rheumatoid Arthritis (OSKIRA). Three pivotal studies are ongoing: two are examining fostamatinib in patients who have had an inadequate response to disease-modifying antirheumatic drugs (DMARDs). These trials, OSKIRA-1 and OSKIRA-2, are both 12-month studies; one six-month study, OSKIRA-3, is studying patients who have had an inadequate response to anti–tumor necrosis factor therapy. A long-term extension study will also examine ongoing tolerability and safety. The primary study endpoints of OSKIRA 1 to 3 include the proportion of patients with ACR20 response criteria versus placebo. The OSKIRA-1 study also has a co-primary endpoint of change from baseline to week 24 in the modified total Sharp score.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Drug Updates Tagged With: Approval, Drugs, FDA, PipelineIssue: March 2013

You Might Also Like:
  • Rheumatology Drug Updates
  • Rheumatology Drug Updates
  • Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib, Bimekizumab
  • Rheumatology Drug Updates

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.